Lazard Asset Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $350K | Sell |
24,184
-17,100
| -41% | -$245K | ﹤0.01% | 1466 |
|
|
2025
Q4 | $588K | Buy |
41,284
+22,198
| +116% | +$218K | ﹤0.01% | 1327 |
|
|
2025
Q3 | $150K | Buy |
19,086
+15,598
| +447% | +$111K | ﹤0.01% | 1640 |
|
|
2025
Q2 | $19K | Sell |
3,488
-7,326
| -68% | -$47.3K | ﹤0.01% | 2128 |
|
|
2025
Q1 | $88K | Buy |
10,814
+2,439
| +29% | +$22.6K | ﹤0.01% | 1839 |
|
|
2024
Q4 | $78K | Sell |
8,375
-131
| -2% | -$1.36K | ﹤0.01% | 1876 |
|
|
2024
Q3 | $90K | Buy |
8,506
+8,356
| +5,571% | +$91K | ﹤0.01% | 1796 |
|
|
2024
Q2 | $0 | Sell |
150
-7,005
| -98% | -$71.9K | ﹤0.01% | 2304 |
|
|
2024
Q1 | $83K | Sell |
7,155
-4,312
| -38% | -$55.1K | ﹤0.01% | 1594 |
|
|
2023
Q4 | $162K | Buy |
11,467
+445
| +4% | +$5.05K | ﹤0.01% | 1468 |
|
|
2023
Q3 | $133K | Buy |
11,022
+5,322
| +93% | +$68.7K | ﹤0.01% | 1525 |
|
|
2023
Q2 | $71K | Sell |
5,700
-9,680
| -63% | -$115K | ﹤0.01% | 1707 |
|
|
2023
Q1 | $170K | Buy |
15,380
+1,187
| +8% | +$14.6K | ﹤0.01% | 1350 |
|
|
2022
Q4 | $173K | Buy |
14,193
+4,356
| +44% | +$49K | ﹤0.01% | 1325 |
|
|
2022
Q3 | $102K | Hold |
9,837
| – | – | ﹤0.01% | 1470 |
|
|
2022
Q2 | $105K | Buy |
9,837
+3,981
| +68% | +$32.8K | ﹤0.01% | 1489 |
|
|
2022
Q1 | $55K | Hold |
5,856
| – | – | ﹤0.01% | 1693 |
|
|
2021
Q4 | $67K | Sell |
5,856
-112,559
| -95% | -$1.25M | ﹤0.01% | 1609 |
|
|
2021
Q3 | $1.13M | Buy |
+118,415
| New | +$1.21M | ﹤0.01% | 1046 |
|
|
2021
Q2 | – | Sell |
-5,657
| Closed | -$55K | – | 1995 |
|
|
2021
Q1 | $55K | Buy |
5,657
+2,763
| +95% | +$42.8K | ﹤0.01% | 1394 |
|
|
2020
Q4 | $66K | Hold |
2,894
| – | – | ﹤0.01% | 1301 |
|
|
2020
Q3 | $40K | Sell |
2,894
-1,833
| -39% | -$26.7K | ﹤0.01% | 1244 |
|
|
2020
Q2 | $71K | Sell |
4,727
-3,259
| -41% | -$39.7K | ﹤0.01% | 1114 |
|
|
2020
Q1 | $73K | Buy |
7,986
+4,338
| +119% | +$41.2K | ﹤0.01% | 1066 |
|
|
2019
Q4 | $35K | Buy |
3,648
+2,739
| +301% | +$25.1K | ﹤0.01% | 1130 |
|
|
2019
Q3 | $7K | Buy |
+909
| New | +$9.87K | ﹤0.01% | 1335 |
|
|
2019
Q2 | – | Sell |
-6,243
| Closed | -$84K | – | 1210 |
|
|
2019
Q1 | $84K | Sell |
6,243
-9,080
| -59% | -$111K | ﹤0.01% | 1045 |
|
|
2018
Q4 | $146K | Buy |
+15,323
| New | +$168K | ﹤0.01% | 886 |
|
|
2015
Q3 | – | Sell |
-90,355
| Closed | -$1.28M | – | 1106 |
|
|
2015
Q2 | $1.28M | Buy |
+90,355
| New | +$1.09M | ﹤0.01% | 673 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Lazard Asset Management's FOLD Position: Q1 2026 in Review
Lazard Asset Management reduced its Amicus Therapeutics (FOLD) stake by 41% in Q1 2026, selling an estimated $245K and leaving 24,184 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #1466.
Lazard Asset Management first reported a position in FOLD in Q2 2015 and has held it in 29 quarters since. The position peaked at $1.28M in Q2 2015. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Lazard Asset Management held 24,184 shares of Amicus Therapeutics worth $350K as of Q1 2026.
- Lazard Asset Management sold 17,100 Amicus Therapeutics shares in Q1 2026, an estimated $245K.
- Amicus Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1466 holding.
- Lazard Asset Management first reported a position in Amicus Therapeutics in Q2 2015 and has held it in 29 quarters since.
- Lazard Asset Management's Amicus Therapeutics position peaked at $1.28M in Q2 2015.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.